United Therapeutics (NASDAQ:UTHR) Announces Earnings Results, Beats Estimates By $0.54 EPS

United Therapeutics (NASDAQ:UTHR) released its quarterly earnings results on Wednesday. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54, Briefing.com reports. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the company earned $4.86 earnings per share.

United Therapeutics Price Performance

NASDAQ:UTHR traded up $3.57 during mid-day trading on Thursday, reaching $258.71. 396,155 shares of the company were exchanged, compared to its average volume of 451,992. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a fifty day moving average of $235.34 and a 200 day moving average of $229.00. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The stock has a market cap of $11.48 billion, a PE ratio of 12.86 and a beta of 0.54.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total value of $77,285.00. Following the transaction, the director now owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total value of $3,724,950.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $32,282.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 325 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the completion of the transaction, the director now directly owns 5,373 shares in the company, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Insiders have sold a total of 138,190 shares of company stock valued at $32,643,561 in the last 90 days. 12.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research analyst reports. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday. Wells Fargo & Company increased their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $306.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.